VIVUS (VVUS) Lower Heading into Obesity 2012 Event; Will Present New Qsymia Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
VIVUS (VVUS) Says EMA CHMP May Recommend Against MAA for Qsiva
September 21, 2012 7:05 AM EDTVIVUS, Inc. (Nasdaq: VVUS) announced that based on preliminary feedback from the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP), the company expects an opinion recommending against approval of the Marketing Authorization Application (MAA) for Qsiva (phentermine/topiramate ER) for the treatment of obesity.... More
VIVUS (VVUS) Says Qsymia Weight-Loss Pill Available in U.S. Market
September 18, 2012 7:02 AM EDTVIVUS, Inc. (Nasdaq: VVUS) today announced the U.S. market availability of Qsymia (pronounced Kyoo sim ee' uh). Qsymia is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as... More
